In Reply We thank Drs Mohamad and Roach for their thoughtful comments on our Research Letter1 and for agreeing with our conclusion that radiotherapy (RT) delays of up to 6 months were not associated with worse overall survival (OS) in men with unfavorable intermediate-risk or high-risk prostate cancer undergoing standard-of-care treatment with RT and androgen deprivation therapy (ADT). This observation may help shared decision-making, especially in the setting of a coronavirus disease 2019 (COVID-19) surge, when daily hospital trips for RT may increase the risk of COVID-19 transmission.2
Dee EC, D’Amico AV, Muralidhar V. Radiation Delay Is Okay, but Where Is the Evidence?—Reply. JAMA Oncol. 2021;7(3):464–465. doi:10.1001/jamaoncol.2020.7618
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.